放化疗联合西妥昔单抗在鼻咽癌治疗中的疗效评估

王晓溪

doi:10.13201/j.issn.1001-1781.2016.15.013

放化疗联合西妥昔单抗在鼻咽癌治疗中的疗效评估

王晓溪^,

- 榆林市第二医院耳鼻咽喉科(陕西榆林, 719000)

详细信息

通讯作者: 王晓溪,E-mail:tianhe0727@sina.com

中图分类号: R739.63

收稿日期: 2016-04-02

Clinical assessment of the radiotherapy and chemotherapy combined with cetuximabin in the treatment of nasopharyngeal carcinoma

WANG Xiaoxi^,

- Department of Otolaryngology, Yulin No.2 Hospital, Yulin, 719000, China

More Information

Corresponding author: WANG Xiaoxi, E-mail: tianhe0727@sina.com

Received Date: 02 April 2016

摘要

摘要: 目的: 评估放化疗联合西妥昔单抗在治疗鼻咽癌中的效果。方法: 鼻咽癌患者78例,按治疗方式分成对照组(42例)和处理组(36例)。对照组患者给予放疗同期顺铂化疗;处理组患者除了对照组中的处理外加用西妥昔单抗。对两组患者进行随访,从近期疗效、远期疗效及不良反应3个方面对比评估放化疗联合西妥昔单抗在鼻咽癌治疗中的效果。结果: 处理组治疗近期有效率(94.44%)显著高于对照组(78.57%),P<0.05。处理组放射性皮炎、口腔黏膜反应、骨髓抑制、放射性脑损伤等不良反应发生率与对照组无显著差异(P>0.05)。处理组中位生存期(55个月)显著长于对照组(48个月),P<0.05;4年总生存率(88.89%)显著高于对照组(69.05%),P<0.05;4年期无疾病进展率处理组(75%)显著高于对照组(59.52%),P<0.05。结论: 放化疗联合西妥昔单抗能够显著提高鼻咽癌患者近、远期疗效,不良反应与对照组相当,值得在临床上推广应用。
- 放射疗法 /
- 化学疗法 /
- 西妥昔单抗 /
- 鼻咽肿瘤 /
- 疗效
Abstract: Objective: The aim of this study is toinvestigate the clinical effect of radiotherapy and chemotherapy combined with cetuximab in the treatment of nasopharyngeal carcinoma.Method: Seventy-eight cases of nasopharyngeal carcinoma patients were divided into control group(n=42) and treatment group(n=36). The control group was treated with radiotherapy and diamminedichloroplatinum; the treatment group was treated with radiotherapy and diamminedichloroplatinum combined with cetuximab. Short-term efficacy, survival time, and adverse reactions were documented during following up in both groups.Result: The efficiency in the treatment group(94.44%) was significantly higher than that in the control group(78.57%), P<0.05. There were no significant difference of adverse reaction including radiodermatitis, oral mucosa reaction, bone marrow inhibition,radiation-induced brain injury between the two groups, P>0.05. The medium survival time of the treatment group(55 months) was significantly longer than that of the control group(48 months), P<0.05. 4-year survival rate in treatment group(88.89%) was significantly higher than that in the control group(69.05%), P<0.05. 4-year diseases free survival(DFS) rate in treatment group(75%) was significantly higher than that in the control group(59.52%), P<0.05.Conclusion: Radiotherapy and chemotherapy combined with cetuximab can significantly improve the treatment efficiency in patients with nasopharyngeal carcinoma, while do not lead to higher rate of adverse reactions. This treatment is worth being promoted in clinical application.
- radiotherapy /
- chemotherapy /
- cetuximab /
- nasopharyngeal neoplasms /
- curative effect

HTML全文

参考文献(11)

[1]	SHEN Q,LIN F,RONG X,et al.Temporal Cerebral Microbleeds Are Associated With Radiation Necrosis and Cognitive Dysfunction in Patients Treated for Nasopharyngeal Carcinoma[J].Int J Radiat Oncol Biol Phys,2016,94:1113-1120.
[2]	XU T,SHEN C,OU X,et al.The role of adjuvant chemotherapy in nasopharyngeal carcinoma with bulky neck lymph nodes in the era of IMRT[J].Oncotarget,2016,7:21013-21022.
[3]	XU T,LIU Y,DOU S,et al.Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma:Results of arandomized phase II study[J].Oral Oncol,2015,51:875-879.
[4]	冼献清,谢民强,江刚.鼻咽癌化疗现状及进展[J].临床耳鼻咽喉头颈外科杂志,2013,27(3):164-168.
[5]	司勇锋,陶仲强.鼻咽癌的综合治疗研究[J].中国耳鼻咽喉头颈外科,2014,21(5):236-240.
[6]	TSAO A,HUI E P,JUERGENS R,et al.Phase II study of TAS-106in patients with platinum-failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer[J].Cancer Med,2013,2:351-359.
[7]	CHEN S H,KUO C C,LI C F,et al.O(6)-methylguanine DNA methyltransferase repairs platinumDNA adductsfollowing cisplatin treatment and predicts prognoses of nasopharyngeal carcinoma[J].Int J Cancer,2015,137:1291-1305.
[8]	CHUA M L,WEE J T,HUI E P,et al.Nasopharyngeal carcinoma[J].Lancet,2016,387:1012-1024.
[9]	NIU X,HU C,KONG L.Experience with combination of cetuximab plus intensity-modulated radiotherapy with or without chemotherapy for locoregionally advanced nasopharyngeal carcinoma[J].J Cancer Research Clin Oncology,2013,139:1063-1071.
[10]	ZHAI R P,YING H M,KONG F F,et al.Experience with combination of nimotuzumab and intensitymodulated radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma[J].Onco Targets Ther,2015,8:3383-3390.
[11]	PERRI F,DELL'OCA I,MUTO P,et al.Optimal management of a patient with recurrent nasopharyngeal carcinoma[J].World J Clin Cases,2014,2:297-300.